CA-VERIMATRIX
1.9.2022 17:46:43 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it will highlight its powerful content protection, anti-piracy and enterprise cybersecurity technologies for streaming services providers, broadcasters, telcos and operators from September 9-12 during this year’s IBC conference at RAI Amsterdam.
The company’s IBC showcase follows a fast-growing number of technology partnerships that underscore the appeal of the cloud-based Verimatrix Streamkeeper solution that’s designed to enable battle-ready, yet streamlined and cost-effective protections for content delivered via nearly any platform type. The IBC conference serves as one of the media and entertainment industry’s most notable venues to feature Verimatrix’s unique zero-code telemetry approach that makes anti-piracy and cybersecurity not only simple and fast, but also cost-effective and designed to encourage integration with other related M&E providers.
IBC Show Highlights:
- Product demos - Verimatrix XTD (Extended Threat Defense), Verimatrix Streamkeeper, Verimatrix Secure Delivery Platform and Verimatrix VCAS (IPTV/DVB)
- 3D hologram – A holographic presentation of Verimatrix Counterspy, the company’s proprietary anti-piracy and app protection security agent that uses proprietary zero code technology
- Partner recognition – Technology partners are critical to Verimatrix’s success, and the company will feature key partners on its partner wall, during demos and in booth videos
The company is set to host two in-booth mixers at its IBC Booth 1.C23 on September 9 and 10 with TiVo, a leader in DVR and advanced television, as well as The Goose House, a popular esports community that Verimatrix sponsors. Verimatrix is also sponsoring a Media and Entertainment Services Alliance (MESA) networking event scheduled for 8-10 p.m. on September 9 at Café Black.
“Today’s countless ways of delivering and consuming entertainment require a modern approach to anti-piracy and cyberattack prevention, but they must be offered as business enablers and value providers versus costs centers. Verimatrix Streamkeeper and Verimatrix XTD are two new solutions engineered to do just that,” said Asaf Ashkenazi, CEO at Verimatrix. “Our theme for IBC 2022 is ‘STREAM ON! Game changing security for streaming & beyond’ and we are excited to showcase a stunning new booth design where we will showcase our latest products alongside our award-winning, legacy content security solutions.”
Verimatrix Streamkeeper stands as a cybersecurity and anti-piracy gamechanger. Its users can implement a comprehensive set of content protection and anti-piracy solutions such as Multi-DRM, Watermarking, App Shield and other countermeasures that allow users to hunt down and take out OTT pirates who often take advantage of premium content that’s left unprotected. Streamkeeper includes Verimatrix's Counterspy technology – the autonomous injection of an anti-piracy and app protection security agent that uses proprietary zero code technology that brings deep, defensive countermeasures as well as the monitoring of clients without the hassle of a huge integration effort.
Verimatrix XTD defends against endpoint attacks by monitoring apps, APIs and unmanaged devices; illuminating blind spots and preventing firewall intrusions -- threats that are not typically covered by existing cybersecurity solutions.
Verimatrix Streamkeeper info is available at www.verimatrix.com/products/streamkeeper.
Verimatrix XTD info is available at www.verimatrix.com/products/extended-threat-defense.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
